Holen Sie sich die Stockscreener-App
4.985
0.00%
0.005
Schlusskurs vom Vortag:
$4.99
Offen:
$4.98
24-Stunden-Volumen:
118.75K
Relative Volume:
0.10
Marktkapitalisierung:
$261.17M
Einnahmen:
$44.12M
Nettoeinkommen (Verlust:
$-156.25M
KGV:
-1.6238
EPS:
-3.07
Netto-Cashflow:
$-154.61M
1W Leistung:
+0.00%
1M Leistung:
+0.81%
6M Leistung:
+3.74%
1J Leistung:
+8.71%
1-Tages-Spanne:
$4.98
$4.99
1-Wochen-Bereich:
$4.97
$4.99
52-Wochen-Spanne:
$2.29
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
Firmenname
2 Seventy Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
60 BINNEY STREET, CAMBRIDGE
Vergleichen Sie TSVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
4.985 | 261.17M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.91 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.20 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
628.63 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.79 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.44 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-06 | Herabstufung | Goldman | Neutral → Sell |
| 2024-01-31 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-13 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-02 | Eingeleitet | Goldman | Buy |
| 2022-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-11-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
2 Seventy Bio Inc Aktie (TSVT) Neueste Nachrichten
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
Bristol Myers Squibb to Acquire 2seventy bio for $5.00 Cash Per Share: Q4 Results Released - Stock Titan
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Finanzdaten der 2 Seventy Bio Inc-Aktie (TSVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2 Seventy Bio Inc-Aktie (TSVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baird William D III | President and CEO |
Mar 17 '25 |
Sale |
4.95 |
5,092 |
25,180 |
1,121,034 |
| Eatwell Victoria | Chief Financial Officer |
Mar 17 '25 |
Sale |
4.95 |
2,592 |
12,817 |
444,387 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
11,095,936 |
54,702,964 |
0 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
5,142,111 |
25,350,607 |
0 |
| Snow Jessica | See Remarks |
Jan 06 '25 |
Sale |
2.79 |
5,114 |
14,289 |
147,365 |
| Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
| Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
| Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
| Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
| Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):